MedPath

Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

Not Applicable
Completed
Conditions
Type 2 Diabetes
Interventions
Other: Hyperoxia Exposure
Other: Normoxia Exposure
Registration Number
NCT05219994
Lead Sponsor
University of Missouri-Columbia
Brief Summary

Our overall goal is to advance our understanding of the contribution of the carotid body chemoreceptors in glucose regulation and the development of type 2 diabetes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • healthy,
  • type 2 diabetes
  • BMI 18-40 kg/m2,
  • non-pregnant,
  • non-breastfeeding,
  • non-nicotine users.
Exclusion Criteria
  • cardiovascular disease including myocardial infarction, heart failure, coronary artery disease, stroke;
  • renal or hepatic diseases;
  • active cancer;
  • autoimmune diseases;
  • immunosuppressant therapy;
  • excessive alcohol consumption (>14 drinks/week);
  • current nicotine use;
  • foot ulcers;
  • diabetic neuropathy;
  • medication directly influencing sympathetic nervous system activity

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Oral Glucose Tolerance TestHyperoxia ExposureSubjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
Oral Glucose Tolerance TestNormoxia ExposureSubjects will consume a 75 g glucose drink within 1-min and monitored for 2 hours.
Primary Outcome Measures
NameTimeMethod
Glucose change in response to OGTT2 hours post glucose ingestion
Insulin change in response to OGTT2 hours post glucose ingestion
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Missouri

🇺🇸

Columbia, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath